NKG2D CARs as cell therapy for cancer.
NKG2D CARs as cell therapy for cancer.
复制标题
DOI：
10.1097/ppo.0000000000000029
复制
发表时间：
2014-03
期刊：
影响因子：
--
通讯作者：
Meehan KR
中科院分区：
文献类型：
--
作者：
Sentman CL;Meehan KR
NKG2D细胞受体及其配体作为一种潜在的攻击肿瘤细胞的策略已经引起了人们的极大兴趣。NKG2D配体在大多数类型的肿瘤上都有表达，与健康细胞相比，它们在肿瘤细胞上的表达具有相对的选择性。基于NKG2D的嵌合抗原受体(CAR)已被开发出几种不同的变体，并进行了广泛的体内机制研究，表明细胞毒性和细胞因子对NKG2D CAR过继T细胞治疗的疗效至关重要。NKG2D CARS以肿瘤细胞为靶点，也以肿瘤微环境内的免疫抑制细胞为靶点。在一定条件下，NKG2D配体可以在非肿瘤组织中表达，因此存在潜在的肿瘤外毒性。在这篇文章中，我们综述了NKG2D作为CAR靶向肿瘤的基础的使用。
The NKG2D cell receptor and its ligands have attracted considerable interest as a potential strategy to attack tumor cells. NKG2D ligands are expressed on most types of tumors, and they demonstrate relative selectivity of ligand expression on tumor cells compared with healthy cells. Several different variants of NKG2D-based chimeric antigen receptors (CAR) have been developed and extensive in vivo mechanistic studies performed demonstrating that cytotoxicity and cytokines are important for the efficacy NKG2D CAR adoptive T cell therapy. NKG2D CARs target tumor cells and they also target immunosuppressive cells within the tumor microenvironment. Under certain conditions, NKG2D ligand expression can be found on non-tumor tissue, so potential off-tumor toxicity remain. In this article, we review the use of NKG2D as a basis for CAR targeting of tumors.